Close Menu

NEW YORK – Myriad Genetics is partnering with the University of Leeds Center for Personalized Medicine and Health (LCPMH) to conduct a clinical utility study of the Prolaris prostate cancer test.

Prolaris analyzes the expression of 31 cell cycle genes, and may be combined with prostate specific antigen testing and Gleason score to gauge the aggressiveness of a patient's prostate cancer over the next decade.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.